INTRODUCTION
The incidence of thyroid cancer has increased considerably in recent decades, and South Korea has had the most prominent increase. 1, 2 According to the Korea National Cancer Incidence (NCI) database, crude and age-standardized cancer incidence rates for thyroid cancer in 2013 were 84.1 per 100,000 (33.4 in men, 134.9 in women) and 60.1 per 100,000 (24.0 in men, 96.6 in women), respectively. 3 Between 1999 and 2013, the age-standardized rate of thyroid cancer incidence notably increased in both men (annual percent change [APC], 22.7%) and women (APC, 20.6%) in Korea 3 ; and thyroid cancer was the most commonly diagnosed cancer in women in 2013. 3 Although it cannot fully explain the increases in thyroid cancer, enhanced detection using high-resolution ultrasonography (US) might be mainly responsible for the increased incidence of thyroid cancer. 4, 5 Because of its socioeconomic effects on the health care system, many concerns related to thyroid cancer screening and to the increases in cancer detection have been raised. 2, 6 Despite the surge in incidence, disease-specific mortality from thyroid cancer reportedly has remained stable. 7, 8 Previously, we reported trends in the age-standardized mortality rates (ASMRs) in Korea from 1985 to 2010 (at 5-year intervals) using national data from Statistics Korea (the statistical office of Korea) and demonstrated a decreasing trend in the thyroid cancer mortality rate between 2000 and 2010. 9 In the current study, we the objective also was to evaluate ASMRs of thyroid cancer up to 2015 and to estimate the APC to identify when significant changes in thyroid cancer mortality occurred in Korea.
MATERIALS AND METHODS

Data Source
Cancer-specific mortality data from 1985 to 2015 were obtained from Statistics Korea. 10 The cause of death was coded and classified according to the International Classification for Diseases, 10th edition code for thyroid cancer (C73). Population data from the Population and Housing Census were also obtained from Statistics Korea.
11
Analysis
The crude mortality rates (CMRs) and ASMRs were calculated for thyroid cancer. ASMRs were determined using the world standard population from the World Health Organization (WHO). 12 We followed the method introduced by Surveillance Research Program of the US National Institutes of Health/National Cancer Institute to calculate ASMRs. We subanalyzed groups according to sex and age, with age classified by as <55 years or 55 years according to a new eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM staging system for thyroid cancer.
To identify significant changes in mortality trends, we performed joinpoint regression analysis, allowing for a maximum of 2 joinpoints using log-linear models. We set the optimal number of joinpoints according to the method described by Muggeo. 13 For each period of the identified trends, we calculated the estimated APC. P values < .05 were considered statistically significant. Statistical analyses were performed using R software (version 3.1.2; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline characteristics of the patients who died from thyroid cancer are presented in Table 1 according to period (1985-1994, 1995-2004, or 2005-2015 (Table 2 ). After 2007, the CMR became steady. This trend was similar in both men and women (Fig. 1A,B) . In the older subgroup (aged 55 years), the CMR reached its highest value of 4.32 (95% CI, 3.86-4.84) per 100,000 in 2004 and then decreased (Fig. 1D) Table 3 ).
DISCUSSION
Recently, it has become widely accepted that the increasing incidence of thyroid cancer is mainly the result of the increased detection of subclinical diseases; and the effectiveness of or the necessity for thyroid cancer screening has become an issue.
2,4,6,14-17 Thus, there is a need to assess mortality from thyroid cancer according to the increases in cancer detection. Most previous studies suggested that the mortality rate for thyroid cancer remained stable. However, based on national statistics data from Korea, the ASMRs of thyroid cancer increased from 1985 to the early 2000s. However, the ASMRs tended to decrease from 2004 in Korea. Data on changes in thyroid cancer mortality in other countries are inconclusive. A recent global study reported thyroid cancer mortality rates in 2012 of 0.6 per 100,000 women and 0.3 per 100,000 men. 8 These findings were similar to the ASMRs reported for 2012 based on the WHO population that we describe in our study. That European group also reported a decrease in thyroid cancer mortality in several countries, particularly among women, from 2000 to 2010. 8 Thyroid cancer mortality decreased, and the reported APC was between 22% and 23% in men and between 22% and 25% in women. However, an increase in thyroid cancer mortality was observed in several countries, including the United States. 8 According to a Surveillance, Epidemiology, and End Results Program cancer statistics review , the overall average APC of thyroid cancer mortality increased slightly by 0.8% between 1992 and 2013 (1.5% in men, 0.4% in women). 18 The reasons for the increased mortality from thyroid cancer between 1985 and 2004 in Korea are not clear. A change in the completeness of the cause-of-death statistics over time might have contributed to such an increase; however, this is regarded as a minor factor. 19 There might have been a true increase in thyroid cancer over this period in Korea. The peak ASMR in the Korean population was >0.8 per 100,000 between 2002 and 2004, as demonstrated in the current study; and it was higher than the peak ASMR reported in the GLOBOCAN 2012 worldwide data (ASMR for thyroid cancer, 0.5 per 100,000; among men, 0.3 per 100,000; among women, 0.6 per 100,000 per 100,000). 20 The increase in the prevalence of obesity 21 and the increased use of medical radiation over this period in Korea are possible causal factors. Moreover, the higher Original Article mean levels of serum thyroid-stimulating hormone in the general population of Korea, compared with those in other populations (probably resulting from a high iodine intake), may have exaggerated the effects of risk factors for thyroid cancer. 22 The exact reason for the decrease in the mortality of thyroid cancer in Korea from 2004 and later is not clear. First, the use of US in cancer screening might have contributed to the early detection and treatment of thyroid cancer. 6, 23 Consequently, the size distribution of detected thyroid cancers has shifted toward smaller lesions. 7, 24 However, investigators observed that, although the increase was mainly because of small tumors, the detection of large tumors also may have increased 1, [25] [26] [27] In addition, the detection of thyroid cancer with regional extension has also increased. 1, 5, 28 It is known that even microcarcinoma, extracapsular extension, lymph node metastasis, and/or extrathyroid extension are identified at presentation in a small fraction of patients (range, 15%-30%). 29 Distant metastases may also present in an even smaller percentage of patients. 30 Therefore, the increased screening for thyroid cancer using neck US may have resulted in the detection of large and/or regional extended tumors as well as small localized tumors. Early treatment of these lesions might have contributed to the observed decrease in mortality.
Second, the increased detection of papillary carcinoma, which has a better clinical outcome compared with other histologic subtypes of thyroid cancer, has also influenced the decrease in disease-specific mortality. 31 Third, the standardization of treatment for thyroid cancer could be another reason for these changes. The Korean Thyroid Association initially published guidelines for patients with thyroid nodules and cancer in 2007. 32 After that, active treatments like total thyroidectomy and radioactive iodine treatment became more popular. Finally, there may be changes in several unknown risk factors. More precise investigations are needed to identify the possible reasons for decreasing rates.
In the early 2000s, health check-up programs became more widespread in Korea. In 1999, the government initiated a national screening program for stomach, breast, cervical, liver, and colorectal cancers. Although thyroid cancer screening was not included in the program, thyroid US can easily be performed at low cost, especially in women who are participating in other screening programs. In 1 study in Korea that assessed the number of US examinations performed at 10 universities and general hospitals between 2001 and 2004, the number of US examinations had doubled, and the number of fine-needle aspirations had increased 4-fold. 33 In another study, the screening rate of thyroid cancer in Korea in 2009 was 13.2% of the total population (8.4% of men and 16.4% of women). 34 The screening rate increased thereafter and was 15.8% and 31.3% in 20 men and women, respectively, in 2011. 35 Recently, Jung et al reported that the ASMR in Korea for most cancer sites, including lung, liver, colorectum, gallbladder, leukemia, brain, and cervix uteri, started to decrease in the early 2000s. 36 The current study has important limitations. First, the method used by Statistics Korea to collect data on the cause of death was changed in 1999. Since then, the cause of death has been supplemented by external data, and the completeness and accuracy of the cause of death has been improved. It is possible that this change influenced the mortality trend until 2000. However, it may not explain the decrease in mortality after 2004. Second, we lacked mortality data according to tumor histology. It would be helpful to analyze thyroid cancer mortality according to histology in the future. Third, we did not demonstrate any direct, specific cause of the decrease in mortality. Therefore, caution is needed when interpreting the association between trends in the mortality rate and the early detection of thyroid cancer.
Thyroid cancer mortality in Korea increased until 2003 and 2004 and then started to decrease. These changes were consistent in both men and women and in older age groups. The increase in the early diagnosis of thyroid cancer, changes in exposure to risk factors, and standardization in diagnosis and treatment might be associated with the decrease in thyroid cancer mortality in Korea. Evidence of over-diagnosis of cancer in a population comes from rapidly increasing rates of diagnosis of certain types of cancer accompanied by a stable death rate. However, the finding that mortality from thyroid cancer has substantially decreased from 2004 in Korea in the era of an "epidemic" of thyroid cancer may suggest a screening effect, or an improvement in the management of thyroid cancer, or other unknown factor(s). Additional studies are required to explore the contributors to changes in thyroid cancer mortality trends in Korea.
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